A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population
This study has been completed.
Sponsor:
Braintree Laboratories
Information provided by:
Braintree Laboratories
ClinicalTrials.gov Identifier:
NCT00425594
First received: January 19, 2007
Last updated: December 20, 2007
Last verified: December 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication.
| Condition | Intervention | Phase |
|---|---|---|
|
Colonoscopy |
Drug: HalfLytely and Bisacodyl Tablets - Formulation 1 Drug: HalfLytely and Bisacodyl Tablets - Formulation 2 Drug: NuLYTELY |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population |
Resource links provided by NLM:
Further study details as provided by Braintree Laboratories:
Primary Outcome Measures:
- Efficacy - preparation quality using a 4-point scale
Secondary Outcome Measures:
- Safety - patient reported preparation related side effects. Pre and post preparation analysis of serum chemistry.
| Estimated Enrollment: | 150 |
| Study Start Date: | January 2007 |
| Study Completion Date: | May 2007 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 6 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Male or female patients who are undergoing colonoscopy for a routinely accepted indication, including:
- Evaluation of BE results
- Endosonography
- Blood in stool
- Anemia of unknown etiology
- Abdominal Pain
- Polypectomy
- Unknown diarrhea or constipation etiology
- Inflammatory bowel disease
- Between 6 and 16 years of age at screening.
- Otherwise in good health, as determined by physical exam and medical history.
- If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse).
- Negative urine pregnancy test at screening, if applicable
- In the investigator's judgment, parent/guardian is mentally competent to provide informed consent to participate in the study.
Exclusion Criteria:
- Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon
- Subjects impacted at screening
- Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- Subjects who are undergoing colonoscopy for foreign body removal and decompression
- Subjects with known difficulties for swallowing tablets
- Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics.
- Subjects who are taking drugs that may affect electrolyte levels with the exception of routine diuretics.
- Subjects with known clinically significant electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia
- Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- Subjects of childbearing potential who refuse a pregnancy test.
- Subjects who are allergic to any preparation components
- Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
- Any condition in parent/guardian associated with poor subject compliance (e.g., substance abuse); inability of parent/guardian to return for scheduled visits with their child.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00425594
Show 26 Study Locations
Show 26 Study LocationsSponsors and Collaborators
Braintree Laboratories
Investigators
| Study Director: | John McGowan | Braintree Laboratories, Inc. |
More Information
No publications provided
| Responsible Party: | John McGowan, Clinical Operations Manager, Braintree Laboratories, Inc. |
| ClinicalTrials.gov Identifier: | NCT00425594 History of Changes |
| Other Study ID Numbers: | F38-25 |
| Study First Received: | January 19, 2007 |
| Last Updated: | December 20, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Braintree Laboratories:
|
colonoscopy bowel preparation prep |
Additional relevant MeSH terms:
|
Bisacodyl Cathartics Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013